Related references
Note: Only part of the references are listed.Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2017)
Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
You-cai Zhu et al.
ONCOTARGETS AND THERAPY (2017)
Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Dana S. Neel et al.
NPJ PRECISION ONCOLOGY (2017)
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
N. Takegawa et al.
ANNALS OF ONCOLOGY (2016)
Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer
Alexios Matikas et al.
CLINICAL LUNG CANCER (2016)
Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy
Samer Tabchi et al.
INVESTIGATIONAL NEW DRUGS (2016)
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
Yoon Jin Cha et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Shiro Fujita et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Neuroendocrine phenotype as an acquired resistance mechanism in ALK-rearranged lung adenocarcinoma
Charline Caumont et al.
LUNG CANCER (2016)
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
Delphine Levacq et al.
LUNG CANCER (2016)
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature
Shi-Yu Jiang et al.
MEDICINE (2016)
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
Matthew G. Oser et al.
LANCET ONCOLOGY (2015)
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
Matthew J. Niederst et al.
NATURE COMMUNICATIONS (2015)
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
Hideko Isozaki et al.
CANCERS (2015)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
Helena A. Yu et al.
CLINICAL CANCER RESEARCH (2013)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Non Small Cell Lung Cancer
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2010)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Share Paper
